Microsoft PowerPoint - 1-Widemann Welcome and FDA update.ppt - Ruxolitinib - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2012-04-08 15:24:08 Bevacizumab Ruxolitinib Food and Drug Administration Pharmacology Pharmaceutical sciences Medicine		Microsoft PowerPoint - 1-Widemann Welcome and FDA update.ppt Add to Reading List Source URL: www.reinscollaboration.org Download Document from Source Website File Size: 20,25 KB Share Document on Facebook

	SUPPLEMENTARY INFORMATION: Specificity and mechanism-‐ of-‐action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) 1. Deter DocID: 1rQNF - View Document
	HAEMATOLOGY AUDIT TEMPLATE DocID: 1pL02 - View Document
	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard DocID: 19YPO - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document
	PDF Document DocID: 16gSu - View Document